Introduction: A 63-year-old male was transferred to our center from an outside hospital after presenting with complaints of left hand numbness and dizziness, which had been ongoing for a few days. A head CT revealed 2 masses, which led to his transfer in order to evaluate for a likely malignancy and subsequently, a metastatic work-up. The patient denied any nausea, vomiting, diarrhea, constipation, abdominal pain, fevers, melena, and hematochezia. He also denied any prior endoscopic procedures. The patient had a contrast CT of the chest, abdomen, and pelvis, which revealed a 4 x 5-cm right atrial mass (later thought to be a thrombus based on MRI), and a 9 x 7-cm mid small bowel mass with surrounding lymphadenopathy and fat stranding, concerning for a primary small intestinal malignancy. Small bowel enteroscopy was performed and a large circumferential, fungating, ulcerated, and infiltrated mass with no bleeding was found in the proximal jejunum at 50-60 cm from the pylorus. This was biopsied and pathology returned positive for metastatic melanoma. After further evaluation, the patient was also found to have a lesion on the skin of his back, which was also biopsied and returned positive for melanoma in situ. The patient was then started on whole brain radiation and trametinib for palliative therapy. The patient underwent a complicated hospital course, which ultimately resulted in comfort care measures and ultimately, expiration. Small bowel tumors only account for 3-6% of all GI tumors, and only 1.5-4% of GI metastases from cutaneous melanoma are ever diagnosed in a patient’s lifetime. Our case highlights a rare presentation that lent itself to diagnosis via push enteroscopy. While there is some suggestion of the possibility for primary GI melanoma, some authors have suggested that there is no such entity and that they all result from a non-GI primary site, such as a regressed cutaneous source. The gold standard for therapy at this time remains surgical resection of metastatic bowel, but as a means of palliation and not cure. Newer systemic chemotherapies and immunotherapies are being FDA-approved in recent years, which may show promise in the coming future.